Corrigendum to “Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes”

Potmešil P and Szotkowská R. Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes. Ther Adv Chronic Dis 2020; 11: 1–11. DOI: 10.1177/2040622320964152.

In the above-referenced article, after the paper is published further changes are made in Tables 2 and 3.

Table 2.

Selected biotransformation data for drugs taken by the patient.

Drug name	Metabolism	Substrate of CYP enzymes	Inhibitor of CYP enzymes?	Inductor of CYP enzymes?	Hepatic side effects of the drug written in SPC?	Effect of renal insufficiency on pharmacokinetics?	Reference SPC, date of SPC revision	Other references
Amlodipine 5 mg daily	CYP enzymes	3A4	Yes: 1A2, 2C9/19, 3A4	No	Very rare	No	Agen® 2016	Wishart et al.4
Anastrozole 1 mg daily	CYP enzymes, UGT	3A4/5/7 2C8, 2D6, 2B6	Yes: 1A2, 2C9, 3A4	No	Very rare	No	Arimidex®	Hertz et al.,3 Wishart et al.,4 Isaacs et al.39
Betaxolol 20 mg daily	CYP enzymes	1A2, 2D6	Yes: 2D6	No	No	Yes, the dosage should be reduced if creatinine clearance <20 ml/min.	Betamed® 2013	Wishart et al.4
Hydrochlorothiazide 12.5 mg daily	Not metabolized in the liver	N/A	N/A	N/A	Yes, rare	Yes, hydrochlorothiazide is contraindicated if creatinine clearance <30 ml/min.	Micardis Plus® Hydrochloro-thiazide Léčiva®
Gliquidone 60 mg daily	CYP enzymes	3A4, 2C9	3A4	No	No	No	Glurenorm® 2016
Metformin 500 mg daily	No metabolism, renal route of elimination	No	No	No	Very rare	Yes	Metformin Zentiva ® 2017
Rilmenidine 2 mg daily	Very modest biotransformation	Yes	No	No	no	No; if creatinine clearance >15 ml/min.	Tenaxum® 2017
Rosuvastatin 20 mg daily	CYP enzymes	Mainly 2C9; 2C19, 3A4, 2D6	No	No	Possible AST, ALT increase	No	Crestor® 2017
Previous tamoxifen 20 mg daily	CYP enzymes	Mainly 3A4/5,2D6 Then 2B6, 2C9/19	Yes:1A2, 2D6	No	Very rare	No	Tamoxifen Ebewe® 2016	Wishart et al.,4 Isaacs et al.39
Telmisartan 80 mg daily before hospitalization (40 mg daily during hospitalization)	By conjugation to acylglucuronide	No	Yes: 2C19	No	Rare, in Japanese	No	Micardis® 2016	Wishart et al.,4 Weiss et al.36

CYP enzymes, biotransformation enzymes belonging to the cytochrome P450 family; N/A, not applicable; SPC, summary of product characteristics; UGT, uridine diphosphate glucuronosyltransferase. Drugs highlighted in bold (anastrozole, meformin, rosuvastatin, tamoxifen) were not prescribed during hospitalization. The other drugs (not highlighted in bold) were taken before admission to the hospital and also during the hospital care.

Table 3.

Effect of drugs on the transporters involved in pharmacokinetic processes or the handling of bilirubin and bile salts.

Transporter	BSEP	BCRP	MDR1 (P-gp)	MRP2	MRP3	MRP4	NTCP	OATP1B1	OCT1	Deferm et al.,37 Giacomini and Sugiyama,40 Jansen54
Other name	ABC B11	ABC G2	ABC B1	ABC C2	ABC C3	ABC C4	SLC10 A1	SLCO1B1	SLC22A1	Wishart et al.,4 Konig et al.,33 Deferm et al.,37 Jansen,54 Fernández-Murga et al.55
Hepatocyte membrane	Canalicular apical	Canalicular apical	Canalicular apical	Canalicular apical	Sinusoidal basolateral	Sinusoidal basolateral	Sinusoidal basolateral	Sinusoidal basolateral	Sinusoidal basolateral	Deferm et al.,37 Jansen,54 Fernández-Murga et al.55
Function	Efflux	Efflux	Efflux	Efflux	Efflux	Efflux	Uptake	Uptake	Uptake	Deferm et al.,37 Fernández-Murga et al.55
Amlodipine	?	Inhibitor	Substrate, inhibitor	?	?	?	?	?	?	Wishart et al.,4 Yang et al.,16 Giacomini and Sugiyama,40 Ivanyuk et al.53
Anastrozole	?	?	Non-substrate non-inhibitor	?	?	?	?	?	?	Wishart et al.,4 Yang et al.,16 Giacomini and Sugiyama 40
Betaxolol	?	?	Substrate non-inhibitor	?	?	?	?	?	?	Wishart et al.,4 Yang et al.16
Hydro- chlorothiazide	?	?	?	?	?	Renal MRP4 substrate, inhibitor	?	?	?	Wishart et al.,4 Yang et al.,16 Ivanyuk et al.53
Gliquidone	?	?	Substrate, inhibitor	?	?	?	?	?	?	Wishart et al.,4 Yang et al.16
Metformin	Inhibitor	?	Non-substrate, non-inhibitor	?	?	?	?	?	Substrate, inhibitor	Deferm et al.,37 Morris and Morse,51 Ivanyuk et al.53
Rilmenidine	?	?	?	?	?	?	?	?	?	Wishart et al.,4 Yang et al.16
Rosuvastatin	Substrate	Substrate	Non-substrate, non-inhibitor	Substrate	?	Substrate	Substrate	Substrate inhibitor	?	Wishart et al.,4 Giacomini and Sugiyama,40 Hu et al.,41 Corsini and Bortolini,49 Morris and Morse51
previous tamoxifen	Substrate, Inhibitor	Substrate	Substrate: induces MDR1 expression inhibits its action.	Inhibitor	Inhibitor	Inhibitor	?	?	OCTN2, inhibitor	Wishart et al.,4 Keppler,35 Deferm et al.,37 Kock et al.,47 Ivanyuk et al.53
Telmisartan	Inhibitor	Inhibitor	Inhibitor	Inhibitor, substrate	?	?	?	?	Inhibitor	Wishart et al.,4 Weiss et al.,36 Hu et al.,41 Ivanyuk et al.53

BCRP/ABCG2, breast cancer resistant protein/ATP-binding cassette subfamily G2; BSEP/ABCB-11, bile salt export pump/ATP-binding cassette protein subfamily B-11; MDR-1, multidrug resistance protein-1 or P-glycoprotein is an expression for ABCB1; MRP-2/ABCC2, multidrug resistance-associated protein-2/ATP-binding cassette protein subfamily C 2; MRP-3/ABCC3, multidrug resistance-associated protein-3/ATP-binding cassette protein subfamily C-3; MRP-4/ABCC4, multidrug resistance-associated protein-4/ATP-binding cassette protein subfamily C-4; NTCP, sodium taurocholate co-transporter polypeptide that is, solute carrier family 10 transporter A1; OATP1B1, organic anion transport protein 1B1 that is, SLCO 1B1, solute carrier organic anion transporter family member 1B1; OCT1, organic cation transporter, that is, SLC22A1, solute carrier family 22 transporter A1; OCTN2, organic cation/carnitine transporter.

“?” means that information regarding the effect of the drug on the transporter was not found in Drugbank database or in other literature sources specified in the right-hand column of Table 3.

Note: Drugs highlighted in bold (anastrozole, metformin, rosuvastatin and previous tamoxifen) were not prescribed in the hospital. The other drugs (not highlighted in bold) were taken before admission to the hospital and also during the hospital care.

The online version of the paper has been corrected.